These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25781074)

  • 1. Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Palmer BD; Sutherland HS; Blaser A; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA; Thompson AM
    J Med Chem; 2015 Apr; 58(7):3036-59. PubMed ID: 25781074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824).
    Thompson AM; Sutherland HS; Palmer BD; Kmentova I; Blaser A; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
    J Med Chem; 2011 Oct; 54(19):6563-85. PubMed ID: 21846109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Kmentova I; Sutherland HS; Palmer BD; Blaser A; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA; Thompson AM
    J Med Chem; 2010 Dec; 53(23):8421-39. PubMed ID: 21069962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Blaser A; Palmer BD; Sutherland HS; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Thompson AM; Denny WA
    J Med Chem; 2012 Jan; 55(1):312-26. PubMed ID: 22148391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Palmer BD; Thompson AM; Sutherland HS; Blaser A; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
    J Med Chem; 2010 Jan; 53(1):282-94. PubMed ID: 19928920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).
    Cherian J; Choi I; Nayyar A; Manjunatha UH; Mukherjee T; Lee YS; Boshoff HI; Singh R; Ha YH; Goodwin M; Lakshminarayana SB; Niyomrattanakit P; Jiricek J; Ravindran S; Dick T; Keller TH; Dartois V; Barry CE
    J Med Chem; 2011 Aug; 54(16):5639-59. PubMed ID: 21755942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and anti-tubercular activity of 2-nitroimidazooxazines with modification at the C-7 position as PA-824 analogs.
    Kang YG; Park CY; Shin H; Singh R; Arora G; Yu CM; Lee IY
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3650-3. PubMed ID: 26199118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biarylmethoxy 2-nitroimidazooxazine antituberculosis agents: Effects of proximal ring substitution and linker reversal on metabolism and efficacy.
    Thompson AM; Blaser A; Palmer BD; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3804-9. PubMed ID: 26253632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Thompson AM; Blaser A; Anderson RF; Shinde SS; Franzblau SG; Ma Z; Denny WA; Palmer BD
    J Med Chem; 2009 Feb; 52(3):637-45. PubMed ID: 19099398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.
    Upton AM; Cho S; Yang TJ; Kim Y; Wang Y; Lu Y; Wang B; Xu J; Mdluli K; Ma Z; Franzblau SG
    Antimicrob Agents Chemother; 2015 Jan; 59(1):136-44. PubMed ID: 25331696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.
    Thompson AM; Blaser A; Palmer BD; Anderson RF; Shinde SS; Launay D; Chatelain E; Maes L; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2583-2589. PubMed ID: 28462832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis.
    Kour G; Kumar A; Singh PP; Sharma S; Bhagat A; Vishwakarma RA; Ahmed Z
    Pulm Pharmacol Ther; 2016 Oct; 40():44-51. PubMed ID: 27457685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.
    Li X; Manjunatha UH; Goodwin MB; Knox JE; Lipinski CA; Keller TH; Barry CE; Dowd CS
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2256-62. PubMed ID: 18358721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Chaudhari HK; Pahelkar A
    Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.
    Thompson AM; O'Connor PD; Blaser A; Yardley V; Maes L; Gupta S; Launay D; Martin D; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
    J Med Chem; 2016 Mar; 59(6):2530-50. PubMed ID: 26901446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and evaluation of novel nitrodihydroimidazooxazoles as promising anti-tuberculosis agents.
    Tao X; Gao C; Huang ZG; Luo W; Liu KL; Peng CT; Ding CZ; Li J; Chen SH; Yu LT
    Bioorg Med Chem Lett; 2019 Sep; 29(17):2511-2515. PubMed ID: 31353295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles.
    Kim P; Zhang L; Manjunatha UH; Singh R; Patel S; Jiricek J; Keller TH; Boshoff HI; Barry CE; Dowd CS
    J Med Chem; 2009 Mar; 52(5):1317-28. PubMed ID: 19209889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Pyrimidines as Antitubercular Agents.
    Inoyama D; Paget SD; Russo R; Kandasamy S; Kumar P; Singleton E; Occi J; Tuckman M; Zimmerman MD; Ho HP; Perryman AL; Dartois V; Connell N; Freundlich JS
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311070
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis, structure and biological evaluation of novel bicyclic nitroimidazole derivatives.
    Zaprutko L; Zwawiak J; Augustynowicz-Kopeć E; Zwolska Z; Bartoszak-Adamska E; Nowicki W
    Arch Pharm (Weinheim); 2012 Jun; 345(6):463-7. PubMed ID: 22266946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
    Thompson AM; O'Connor PD; Marshall AJ; Blaser A; Yardley V; Maes L; Gupta S; Launay D; Braillard S; Chatelain E; Wan B; Franzblau SG; Ma Z; Cooper CB; Denny WA
    J Med Chem; 2018 Mar; 61(6):2329-2352. PubMed ID: 29461823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.